monooxygenase DBH like 2, pseudogeneGenealiases: []
Q-omics provides the consensus-scored MOXD2P profile across patient tissues and cancer cell-line models. MOXD2P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MOXD2P is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, MOXD2P RNA expression shows 8,488 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight BLCA, KIRC, and ESCA as cancer lineages where MOXD2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MOXD2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MOXD2P survival associations across molecular data types. MOXD2P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MOXD2P RNA expression–survival associations across cancer types. High MOXD2P expression shows unfavorable associations in BLCA, MESO, HNSC, THCA and SKCM, but favorable associations in STAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for MOXD2P RNA expression.
This table summarizes MOXD2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MOXD2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MOXD2P shows lower tumor expression in BRCA and higher tumor expression in KIRC and COAD. The KIRC box plot shows higher MOXD2P RNA expression in tumor versus normal tissue (log2 FC = +0.016, t-test p < 0.001).
This table shows molecular features associated with MOXD2P in patient tissues and cancer cell lines. In patient samples, MOXD2P shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
